Dr Kellie Charles

Senior Lecturer
Pharmacology, School of Medical Sciences
Bosch Institute

D06 - Blackburn Building
The University of Sydney
NSW 2006 Australia

T: +61 2 9036 5239

Research interests

Dr Charles' research aims to investigate the interactions between malignant cells and immune cells that regulate tumour progression.Malignant cells secrete cytokines and chemokines that alter the phenotype and behaviour of tumour-associated leucocytes to promote tumour growth and orchestrate the immunosuppressant behaviour of the adaptive immune responses. Inhibiting the communication between cancer cells and immune cells is becoming an exciting potential target for cancer intervention strategies. Dr Charles conducts translational and clinical studies aimed to identify new molecular targets in cancer and in collaboration with biological chemists at the University of Sydney design and evaluate new cancer therapeutic agents.


Proteomics; Pharmacology; Inflammation; Colorectal cancers

International links

United Kingdom. (Centre of Cancer and Inflammation Institute of Cancer and CRUK Clinical School School of Medicine and Dentistry Queen Mary, University of London and Barts London, UK, EC1M6BQ) Collaboration with Prof Frances Balkwill and Dr Thorsten Hagemann.


2014 | 2013 | 2012 | 2011 | 2010 | 2009


  • Diakos, C., Charles, K., McMillan, D., Clarke, S. (2014), Cancer-related inflammation and treatment effectiveness. The Lancet. Oncology. 15(11), e493-e503. [Abstract]


  • Guthrie, G., Charles, K., Roxburgh, C., Horgan, P., McMillan, D., Clarke, S. (2013), The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Critical Reviews in Oncology/Hematology. 88(1), 218-230. [Abstract]
  • Elens, L., Nieuweboer, A., Clarke, S., Charles, K., de Graan, A., Haufroid, V., van Gelder, T., Mathijssen, R., van Schaik, R. (2013), Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. Pharmacogenetics and Genomics. 23(3), 148-155. [Abstract]
  • Elens, L., Nieuweboer, A., Clarke, S., Charles, K., de Graan, A., Haufroid, V., Mathijssen, R., van Schaik, R. (2013), CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Pharmacogenomics. 14(2), 137-149. [Abstract]


  • Chua, W., Clarke, S., Charles, K. (2012), Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer. Supportive Care in Cancer. 20(8), 1869-1874. [Abstract]


  • Clarke, S., Chua, W., Moore, M., Kao, S., Phan, V., Tan, C., Charles, K., McMillan, D. (2011), Use of inflammatory markers to guide cancer treatment. Clinical Pharmacology and Therapeutics. 90(3), 475-478. [Abstract]
  • Chua, W., Kho, P., Moore, M., Charles, K., Clarke, S. (2011), Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. Critical reviews in oncology/hematology. 79(3), 224-50. [Abstract]
  • Chua, W., Charles, K., Baracos, V., Clarke, S. (2011), Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. British Journal of Cancer. 104(8), 1288-1295. [Abstract]


  • Moore, M., Chua, W., Charles, K., Clarke, S. (2010), Inflammation and cancer: causes and consequences. Clinical Pharmacology and Therapeutics. 87(4), 504-508. [Abstract]


  • Chua, W., Moore, M., Charles, K., Clarke, S. (2009), Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer. Current Opinion in Molecular Therapeutics. 11(6), 611-622. [Abstract]
  • Charles, K., Kulbe, H., Soper, R., Escorcio-Correia, M., Lawrence, T., Schultheis, A., Chakravarty, P., Thompson, R., Kollias, G., Smyth, J., Balkwill, F., Hagemann, T. (2009), The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. Journal of Clinical Investigation. 119(10), 3011-3023. [Abstract]